Locate providers:   

Candela Continues Scientific Leadership in Aesthetic Device Field With 18 Industry-Leading Abstracts at ASLMS

 

Studies Presented Reinforce Efficacy of Leading Device For Pain Reduction during Laser Procedures

WAYLAND, Mass.--(BUSINESS WIRE)--April 14, 2008--Candela Corporation (NASDAQ:CLZR), a global leader in aesthetic laser solutions, announced today that its technology was discussed by the world's leading laser experts in 18 presentations during the 28th Annual Conference of the American Society for Laser Medicine and Surgery, held April 2-6 in Kissimmee, Florida.

The presentations included the latest in research and clinical findings for the treatment of rosacea, and hemangiomas as well as hair removal, wrinkle reduction, skin tightening, and next generation Candela treatment of acne showing positive results.

    "The top physicians in the world continue to look to Candela for innovative solutions to the multitude of medical and aesthetic patient care challenges," says Robert LaRoche, Vice President of Global Marketing from Candela. "The 18 presentations highlight the company's commitment to working with our customers to develop technologies that will deliver improved efficacy and patient comfort while optimizing the patient experience."


One of Candela's newest products, the Serenity(TM) Pro, garnered the attention of the attendees at the company's booth, at multiple sessions on hair removal and skin rejuvenation, and during a dinner event which included presentations by Dr. Natalie Fournier from the Center Commercial La Croisee in Clapiers, France and Dr. E. Dwayne Lett from the Lett Center of Aesthetic and Reconstructive Surgery & Medi-Spa in Lebanon, TN. The Serenity Pro reduces patient discomfort and can reduce patient treatment time by minimizing the stop and start associated with many procedures.

Other products featured in presentations included the Vbeam(R) pulsed dye laser, which has continued to outperform IPL in head-to-head studies, the GentleYAG(R) laser, Smoothbeam(R) diode laser, and the GentleLASE(R) long pulse alexandrite laser.

Scientific abstracts included:

  • Pneumatic Skin Flattening Reduces Pain During Laser Hair Reduction, Eric F. Bernstein - Bryn Mawr, PA

  • Pain and Hair Reduction with a 1064 nm Nd:YAG Laser, Nathalie Fournier - Clapiers, France

  • Comparison Between a New 2940 nm Pulsed Er:YAG Laser and 3 Fractional CO2 Lasers, 3 Months Follow-up, Nathalie Fournier - Clapiers, France

  • Nonablative Skin Tightening with a Variable Depth Heating 1310 nm Wavelength Laser, Macrene Alexiades-Armenakas Yale University School of Medicine and Private Practice - New York, NY

  • Hair Removal with Blended 755/1064 nm Laser Energy, E. Victor Ross, Sarah Davis, K.L. McKinney, Melinda Williams, Christina Dore, Domankevitz Yacov Scripps Clinic - San Diego, CA, Candela Corporation - Wayland, MA

  • Evaluation of Large Spot Size 1450 nm Diode Laser for the Treatment of Facial Acne Vulgaris, Paul M. Friedman, Denise Marquez, Joy Kunishige - DermSurgery Associates - Houston, TX

  • Non-Ablative Treatment of Periorbital Lax Skin Using a 1450 nm Diode Laser, Christine Dierickx, Mark Taylor, Nancy Samolitis, Suzanne Kilmer Laser Clinic Boom - Boom, Belgium, Gateway Aesthetic Institute and Laser Center - Salt Lake City, UT Laser and Skin Surgery Center of Northern California - Sacramento, CA

  • Treatment of Infantile Hemangioma Using the Long Pulsed GentleYAG Laser, Guoyu Zhou, Linyue Shen, Zhiyuan Zhang Ninth People's Hospital Affiliated to Jiaotong University Medical College - Shanghai, China

  • Outcomes of Childhood Hemangiomas Treated with the Pulsed Dye Laser with Dynamic Cooling: A Retrospective Cart Analysis, Carina Rizzo, Lori Brightman, Roy G. Geronemus New York University Skin and Cancer Unit, Laser & Skin Surgery Center of New York - New York, NY

  • Treatment Endpoints for Port Wine Stains and Hemangiomas with the 595 nm and 755 nm Lasers, Leonid Izikson, R. Rox Anderson Laser and Cosmetic Dermatology Center and Wellman Center for Photomedicine Massachusetts General Hospital, Harvard Medical School - Boston, MA

  • Rosacea Treatment Using the New-Generation, High Energy,595 nm, Long Pulse-Duration Pulsed Dye Laser, Eric Bernstein, Albert Kligman Main Line Center for Laser Surgery - Bryn Mawr, PA, S.K.I.N. Inc. - Conshohocken, PA

  • Is There a Place for the Pulsed Dye laser in the Treatment of Psoriasis? An Analysis of 335 Treated Lesions, Jean-Michel Mazer, Louis Dubertret - St-Louis Hospital - Paris, France

  • A Comparison of Long-Pulsed Dye Laser and Intense Pulsed Light for the Treatment of the Facial Telangiestatias: A Randomized Controlled Trial, Peter Nymann, Lene Hedelund, Merete Haedersdal Bispebjerg University Hospital - Copenhagen, Denmark

  • Long-Pulsed Dye Laser ABD Intense Pulsed Light for the Treatment of Chronic Radiodermatitis After Breast Cancer: A Randomized Controlled Trial, Peter Nymann, Lene Hedelund, Merete Haedersdal Bispebjerg University Hospital - Copenhagen, Denmark

  • Treatment of Infraorbital Darkening with the 595nm Pulsed Dye Laser, Jerome M. Garden MD, Yacov Domankevitz PhD, Dina Yaghmai MD, Abnoeal D. Bakus PhD, Northwestern University, Chicago, IL

  • Purpura Against Purpura-Free Pulsed Dye Laser Treatments of Rosacea: A Comparative Study, Jean-Michel Mazer - Paris, France

    To receive a comprehensive listing of the abstracts, please email jane.smith@candelalaser.com.

    About CANDELA: Candela Corporation manufactures, and distributes innovative clinical solutions that enable physicians, surgeons, and personal care practitioners to treat selected cosmetic and medical conditions using lasers, aesthetic laser systems, and other advanced technologies. Founded near Boston in 1970, the company markets and services its products in over 70 countries from offices and distributors in the United States, Europe, Japan, China and other Asian locations. Candela established the aesthetic laser market 19 years ago, and currently has an installed base of an estimated 12,000 lasers worldwide. Visit Candela on the Web at http://www.candelalaser.com.

    Safe Harbor Statement: Except for the historical information contained herein, this news release contains forward-looking statements that constitute Candela's current intentions, hopes, beliefs, expectations or predictions of the future, which are therefore inherently subject to risks and uncertainties. Such statements may relate to, among other things, our future revenue, gross margin, expense levels and earnings, our growth prospects, market acceptance of our products, the strength of our distribution channels, our ability to add new products, our ability to expand regulatory approvals and the liquidity of our common stock. The risks and uncertainties that may affect forward-looking statements include, among others: the cancellation or deferral of customer orders, the risk of an adverse judgment in the patent litigation with Palomar Medical Technologies, Inc., the risk of an adverse judgment in the CardioFocus patent litigation, the risk of an adverse judgment in the securities class action lawsuit brought in early April, dependence on a small number of strategic distribution relationships, difficulties in the timely development and market acceptance of new products, unanticipated increases in expenses, market developments that vary from the current public expectations concerning the growth of the laser industry, increased competitive pressures, changes in economic conditions, or difficulties in obtaining timely regulatory approvals. Further information on factors that could affect Candela's performance is included in Candela's periodic reports filed with the SEC. Candela cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Candela expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Candela's expectations or any change in events, conditions or circumstances on which any such statement is based.